Due to advances in diagnosis and treatment of transthyretin cardiac amyloidosis (ATTR-CA) in the last decade, there has been great interest in identifying patients at risk for this disease. Both diseases of the elderly, concomitant ATTR-CA and severe aortic stenosis (AS) have been increasingly recognized, with an estimated prevalence of ATTR-CA in AS to be 5–20 % [ ]. Many patients with ATTR-CA are high-risk for surgical aortic valve replacement, with prior studies showing these patients to have poor outcomes after surgery [ ]. However, the advent of transcatheter aortic valve replacement (TAVR) has offered new hope for this high-risk surgical population. In the TAVR era, the two primary questions that need to be investigated further are: